Injury TraumaticNCT06292039
Human-centered Injury Thrivorship Pathway for Survivors of Physical Trauma
A study testing Human-Centered Injury Thrivorship Pathway in people with Injury Traumatic and Survivorship, run by University of California, San Francisco at 1 site in United States.
Trial summary
The goal of this clinical trial is to pilot and evaluate a human-centered injury thrivorship pathway in injury survivors. The main question it aims to answer is: Is the pathway appropriate, acceptable, and feasible to meet the medical and social needs of injury survivors? Injury survivors will be purposively sampled… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Injury Traumatic, Survivorship, Trauma Injury
- What is being tested?
- Human-Centered Injury Thrivorship Pathway
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2027to Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient ≥ 18 years old presenting with a physical injury to Zuckerberg San Francisco General Hospital
- Admitted to the hospital ≥ 24 hours
- Discharged from the hospital alive
- San Francisco resident or unhoused in San Francisco
- Capacity for informed consent
Who cannot join
- Patient < 18 years old
- Deceased during index hospitalization
- Unable to provide informed consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Zuckerberg San Francisco General Hospital
San Francisco, California, 94110
Marissa A Boeck, MD, MPH, 415-502-4745, marissa.boeck@ucsf.edu
About this study
Official title: Identifying & Addressing Unmet Needs of Injury Survivors at a Safety Net Hospital in San Francisco
The goal of this clinical trial is to pilot and evaluate a human-centered injury thrivorship pathway in injury survivors. The main question it aims to answer is:
- Is the pathway appropriate, acceptable, and feasible to meet the medical and social needs of injury survivors?
Injury survivors will be purposively sampled to enroll in the pathway and asked to participate in in-depth interviews and their use of pathway resources will be tracked.
- Conditions
- Injury Traumatic, Survivorship, Trauma Injury
- Being tested
- Human-Centered Injury Thrivorship Pathway
- Keywords
- Social determinants of health, Community-engaged research, Unmet needs
- Medical subject headings
- Wounds and Injuries, Accidental Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Human-Centered Injury Thrivorship PathwayOther
Enrollment in the human-centered injury thrivorship pathway.
| Study group | Role | What they receive |
|---|---|---|
| Injury Thrivorship Pathway | Experimental | Enrollment in the human-centered injury thrivorship pathway. Receives: Other: Human-Centered Injury Thrivorship Pathway |
What is being measured
The primary outcome is the main question the study is designed to answer.
Early Implementation Outcomes - Acceptability, Appropriateness, Feasibility
Early implementation outcomes will be assessed via purposive sampling of pathway participants, their caregivers, and trauma care stakeholders for in-depth semi-structured interviews. "Acceptability is the perception among implementation stakeholders that a given treatment, service, practice, or innovation is agreeable, palatable, or satisfactory. Appropriateness is the perceived fit, relevance, or compatibility of the innovation or evidence based practice for a given practice setting, provider, or consumer; and/or perceived fit of the innovation to address a particular issue or problem. Feasibility is defined as the extent to which a new treatment, or an innovation, can be successfully used or carried out within a given agency or setting."
Measured: 8-12 weeks post-pathway enrollment
Secondary outcomes (4)
Participant pathway resource utilization - type
Participant engagement with applicable pathway resources will be tracked by type of resource(s) accessed
Measured: 8-12 weeks post-pathway enrollment plus subsequent time points if continued resource engagement until study completion up to 1 year
Participant pathway resource utilization - frequency
Participant engagement with applicable pathway resources will be tracked by frequency of use of the resource(s)
Measured: 8-12 weeks post-pathway enrollment plus subsequent time points if continued resource engagement until study completion up to 1 year
Participant pathway resource utilization - duration
Participant engagement with applicable pathway resources will be tracked by duration of use of the resource(s)
Measured: 8-12 weeks post-pathway enrollment plus subsequent time points if continued resource engagement until study completion up to 1 year
Participant pathway resource utilization - % utilized
Participant engagement with applicable pathway resources will be tracked by overall % of resources utilized out of resource(s) offered
Measured: 8-12 weeks post-pathway enrollment plus subsequent time points if continued resource engagement until study completion up to 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Mar 2024
- Study startJan 2027 (estimated)
- Primary completionJun 2027 (estimated)
- Study completionJun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Injury TraumaticStudies of the same condition, open and under way.
- More trials run by University of California, San FranciscoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 25 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Collaborators
- National Center for Advancing Translational Sciences (NCATS)
- Responsible party
- Sponsor
- Investigators
- Marissa A Boeck, MD, MPH, Principal investigator, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06292039
- Sponsor's protocol ID
- P0555788
- Other IDs
- 2KL2TR001870
- Status last verified
- Apr 2026
- First submitted
- 14 Feb 2024
- Last updated
- 1 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The investigators are undecided how individual participant data will be shared with other researchers, which the investigators will update prior to the initial recruitment date. The primary outcome will be qualitative data from in-depth semi-structured interviews linked to participant demographic and clinical information. The secondary outcome will be quantitative based on resource utilization, also linked to participant demographic and clinical information.
Publications
Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, Griffey R, Hensley M. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health. 2011 Mar;38(2):65-76. doi: 10.1007/s10488-010-0319-7.
PubMed 20957426
Study at a glance
From the registry record, last updated by the sponsor on 1 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Identifying & Addressing Unmet Needs of Injury Survivors at a Safety Net Hospital in San Francisco
- ClinicalTrials.gov ID
- NCT06292039
- Acronym / sponsor ID
- P0555788
- Conditions
- Injury Traumatic, Survivorship, Trauma Injury
- Keywords
- Social determinants of health, Community-engaged research, Unmet needs
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 25 participants (estimated)
- Lead sponsor
- University of California, San FranciscoUniversity, hospital or other
- Collaborators
- National Center for Advancing Translational Sciences (NCATS)
- Study start
- Jan 2027 (estimated)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- Jun 2027 (estimated)
- First posted
- 4 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to pilot and evaluate a human-centered injury thrivorship pathway in injury survivors. The main question it aims to answer is:
- Is the pathway appropriate, acceptable, and feasible to meet the medical and social needs of injury survivors?
Injury survivors will be purposively sampled to enroll in the pathway and asked to participate in in-depth interviews and their use of pathway resources will be tracked.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Injury Thrivorship Pathway | Experimental | Other: Human-Centered Injury Thrivorship PathwayEnrollment in the human-centered injury thrivorship pathway. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patient ≥ 18 years old presenting with a physical injury to Zuckerberg San Francisco General Hospital
- Admitted to the hospital ≥ 24 hours
- Discharged from the hospital alive
- San Francisco resident or unhoused in San Francisco
- Capacity for informed consent
Key exclusion criteria (3 listed)
- Patient < 18 years old
- Deceased during index hospitalization
- Unable to provide informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Human-Centered Injury Thrivorship PathwayEnrollment in the human-centered injury thrivorship pathway. | Other | Injury Thrivorship Pathway |
Primary outcome
Early Implementation Outcomes - Acceptability, Appropriateness, Feasibility
Time frame: 8-12 weeks post-pathway enrollment
Early implementation outcomes will be assessed via purposive sampling of pathway participants, their caregivers, and trauma care stakeholders for in-depth semi-structured interviews. "Acceptability is the perception among implementation stakeholders that a given treatment, service, practice, or innovation is agreeable, palatable, or satisfactory. Appropriateness is the perceived fit, relevance, or compatibility of the innovation or evidence based practice for a given practice setting, provider, or consumer; and/or perceived fit of the innovation to address a particular issue or problem. Feasibility is defined as the extent to which a new treatment, or an innovation, can be successfully used or carried out within a given agency or setting."
4 secondary outcomes
Participant pathway resource utilization - type
Time frame: 8-12 weeks post-pathway enrollment plus subsequent time points if continued resource engagement until study completion up to 1 year
Participant pathway resource utilization - frequency
Time frame: 8-12 weeks post-pathway enrollment plus subsequent time points if continued resource engagement until study completion up to 1 year
Participant pathway resource utilization - duration
Time frame: 8-12 weeks post-pathway enrollment plus subsequent time points if continued resource engagement until study completion up to 1 year
Participant pathway resource utilization - % utilized
Time frame: 8-12 weeks post-pathway enrollment plus subsequent time points if continued resource engagement until study completion up to 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 May 2026.
- Background: PubMed 20957426Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, Griffey R, Hensley M. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health. 2011 Mar;38(2):65-76. doi: 10.1007/s10488-010-0319-7.
- Individual participant dataSharing planned: No. The investigators are undecided how individual participant data will be shared with other researchers, which the investigators will update prior to the initial recruitment date. The primary outcome will be qualitative data from in-depth semi-structured interviews linked to participant demographic and clinical information. The secondary outcome will be quantitative based on resource utilization, also linked to participant demographic and clinical information.
Related trials for Injury Traumatic
Recruiting
NightWare and Cardiovascular Health in Women With PTSD
Post Traumatic Stress Disorder, Cardiovascular Diseases
Not yet recruiting
A Transdiagnostic Sleep Health Intervention for Veterans With PTSD
Stress Disorders, Post-Traumatic, Sleep Initiation and Maintenance Disorders
Active, not recruitingObservational study
Transforming Research and Clinical Knowledge in Traumatic Brain Injury Epileptogenesis Project (TRACK-TBI EPI)
Traumatic Brain Injury, Post-traumatic Epilepsy
Not yet recruitingPhase 3
Women Who Are Victims of Violence: Treatment of PTSD Through Reactivation of Traumatic Memories Using Propranolol
Post-Traumatic Stress Disorder, PTSD
Enrolling by invitationPhase 1
Pilot Safety and Exploratory Efficacy of PSC-05 for the Treatment of Chronic Mild Traumatic Brain Injury
Mild Traumatic Brain Injury
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Marissa A Boeck, MD, MPH principal investigator
University of California, San Francisco
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Human-Centered Injury Thrivorship Pathway in people with Injury Traumatic and Survivorship, run by University of California, San Francisco at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marissa A Boeck, MD, MPH (415-502-4745, marissa.boeck@ucsf.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Early Implementation Outcomes - Acceptability, Appropriateness, Feasibility (time frame: 8-12 weeks post-pathway enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06292039, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2026.